30 results about "Alloimmunity" patented technology

Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal, monoclonal, chimeric or humanized, or antigen binding fragments thereof. These antibodies are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as a therapeutic tool in autoimmune and alloimmune conditions.

Novel chimeric proteins are disclosed. The proteins comprise at least two portions. The first portion binds to a first cell and decreases the cell's ability to send a trans signal to a second cell; the second portion sends its own trans signal to the second cell. Methods for making and using these proteins in the treatment of cancer, viral infections, autoimmune and alloimmune diseases are also disclosed, as are pharmaceutical formulations comprising the novel chimeric proteins and genes. Either the proteins themselves or a genetic sequence encoding the protein can be administered. Other methods are also disclosed in which two molecular components result in decrement of a first trans signal from a first cell and the conferring of a second trans signal to a second cell.

RBC and platelet (Plt) alloimmunization requires antigen-matched blood to avoid adverse transfusion reactions. Some blood collection facilities use unregulated Abs to reduce the cost of mass screening, and later confirm the phenotype with government approved reagents. Alternatively, RBC and Plt antigens can be screened by virtue of their associated single nucleotide polymorphisms (SNPs). We developed a multiplex PCR-oligonucleotide extension assay using the GenomeLab SNPStream platform to genotype blood for a plurality of blood group antigen-associated SNPs, including but not limited to: RhD (2), RhC / c, RhE / e, S / s, K / k, Kpa / b, Fya / b, FYO, Jka / b, Dia / b, and HPA-1a / b.

Fusion proteins which act on the OX40 / TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, and alloimmune diseases, as well as cancer.

Novel chimeric proteins are disclosed. The proteins comprise at least two portions. The first portion binds to a first cell and decreases the cell's ability to send a trans signal to a second cell; the second portion sends its own trans signal to the second cell. Methods for making and using these proteins in the treatment of cancer, viral infections, autoimmune and alloimmune diseases are also disclosed, as are pharmaceutical formulations comprising the novel chimeric proteins and genes. Either the proteins themselves or a genetic sequence encoding the protein can be administered. Other methods are also disclosed in which two molecular components result in decrement of a first trans signal from a first cell and the conferring of a second trans signal to a second cell.

Novel chimeric proteins are disclosed. The proteins comprise at least two portions. The first portion binds to a first cell and decreases the cell's ability to send a trans signal to a second cell; the second portion sends its own trans signal to the second cell. Methods for making and using these proteins in the treatment of cancer, viral infections, autoimmune and alloimmune diseases are also disclosed, as are pharmaceutical formulations comprising the novel chimeric proteins and genes. Either the proteins themselves or a genetic sequence encoding the protein can be administered. Other methods are also disclosed in which two molecular components result in decrement of a first trans signal from a first cell and the conferring of a second trans signal to a second cell.

The present invention relates to novel myeloid suppressor cells (MSCs) and to methods of isolating these MSCs are also included. The MSCs of the present invention can be used to treat or prevent autoimmune diseases or alloimmune responses. The MSCs of the present invention may also be used to reduce a T cell response, induce T regulatory cells, and produce T cell tolerance.

The present invention relates (a) to new compounds represented by Formula I: wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, S represents a steroid subunit (steroid moiety) derived from steroid drug with anti-inflammatory activity and L represents a linker molecule linking M and S, (b) to their pharmacologically acceptable salts, prodrugs and solvates, (c) to processes and intermediates for their preparation, and (d) to their use in the treatment of inflammatory diseases and conditions in humans and animals. Such compounds inhibit many cytokines and immune mediators involved in immune responses which cause inflammation, allergy, or alloimmunity, including without limitation IL-1, 2, 4, 5, 6, 10, 12, GMCSF, ICAM, and TNF-α. Importantly, anti-inflammatory steroids exert a direct anti-inflammatory effect through binding to the glucocorticosteroid receptor.

Antibodies to FcRn are provided which are non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal or monoclonal or antigen binding fragment thereof. These antibodies are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as a therapeutic tool in autoimmune and alloimmune conditions.

A method for characterizing the risk a subject will develop an autoimmune and / or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and / or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.

Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer.

Disclosed are methods for detecting antibody in a sample, where the antibody targets an antigen expressed by red blood cells or red blood cell ghosts. Rather than detecting the binding events between a particular antigen antibody pair (as in traditional agglutination based assays) the methods herein allow for multiplexed detection of clinically important allo-immune antibodies to blood group antigens. Specifically the method involves generating fluorescently encoded red blood cells or red blood cell ghosts with known antigen presentation and using them to detect the presence of antibody in serum / plasma with a fluorescent sandwich type immunoassay. The assay results can be read using flow cytometric or fluorescent microscope based imaging techniques.

The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant.

A method for characterizing the risk a subject will develop an autoimmune and / or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and / or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.

A method and composition for inhibiting phagocytosis of blood cells. The method involves providing a nitrophenyl compound or thimerosal with administration of the compound to a host having an auto or alloimmune disease to inhibit phagocytosis of blood cells.

Embodiments of the disclosure concern engineered auto / allo-immune defense receptor (ADR)-expressing T cells that selectively target activated T cells, including pathogenic T cells, to incapacitate them. The chimeric receptors comprise moieties for targeting 4-1BB, 0X40, and CD40L, for example, whose expression is indicative of activated T cells. In particular embodiments, there are methods of preventing or treating conditions associated with activated T cells using adoptive T-cell transfer of cells encoding the ADRs.

A method of improving the lifespan of transfused platelets is described. The method may be useful for patients with alloimmunozation who are refractory to transfused platelets. A method of treating delayed hemolytic transfusion reaction is also described. Also described are PIC1 peptide variants with improved solubility and activity.

Described herein are immunoresponsive cells which are useful for their preventive and therapeutic potential against autoimmune diseases and rejections of solid organ transplants.

Embodiments of the disclosure concern engineered auto / allo-immune defense receptor (ADR)-expressing T cells that selectively target activated T cells, including pathogenic T cells, to incapacitate them. The chimeric receptors comprise moieties for targeting 4-1BB, OX40, and CD40L, for example, whose expression is indicative of activated T cells. In particular embodiments, there are methods of preventing or treating conditions associated with activated T cells using adoptive T-cell transfer of cells encoding the ADRs.

Methods and compositions for the prevention or reduction of platelet transfusion associated complications are provided. The subject methods include modifying donor whole blood or platelets prior to transfusion to prevent or reduce alloimmune platelet refractoriness.

The described invention relates to methods for preventing or treating graft-versus-host disease while preserving a graft-versus-tumor effect, increasing survival of, preserving alloreactivity, or a combination thereof in a patient with a tumor receiving a transplant. The described methods comprise administering to the patient a therapeutic amount of a pharmaceutical composition comprising a Rho kinase inhibitor compound, e.g., telmisartan or related angiotensin receptor blockers, and a pharmaceutically acceptable excipient. The therapeutic amount may be effective to attenuate graft-versus-host disease and to preserve the graft-versus-tumor effect of the transplant.

A method for characterizing the risk a subject will develop an autoimmune and / or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and / or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.

The invention provides an application of JQ1 in preparing organ transplantation immunological rejection inhibiting medicines, in particular an application in preparing medicines for preventing and treating cardiac transplantation immunological rejection. Based upon experiments, it is proved that the survival time of transplanted hearts of an allogeneic mice (C57BL / 6 to BALB / c) in a control group is 7-10 days, while the survival time of transplanted hearts of mice applied with the JQ1 can reach 25 days to the greatest extent, indicating that the JQ1 provided by the invention is beneficial for reducing an alloimmunity reaction and prolonging the survival of transplants. The JQ1, as a novel small-molecule inhibitor, can solve the problem that transplanted organs are low in survival rate for along time due to rejection, and the JQ1 can offer a basis for preparing organ transplantation immunological rejection inhibiting preparations; therefore, an effective approach is provided for treating such chronic end-stage diseases such as liver diseases, renal diseases, cardiac diseases and the like.

The present disclosure describes a pharmaceutical composition comprising at least one antibody and at least one mesenchymal stromal cell-derived protein. Disclosed herein is also the use of said pharmaceutical composition for treating immunological diseases, for example alloimmune and autoimmune diseases. Further disclosed herein is the use of the pharmaceutical composition for immunomodulation.

A method is described for using live mesenchymal stromal cells (MSCs) in a way which allows for identification of patients likely to respond to immunosuppressive treatment using MSCs. The method involves contacting a sample from said patient with live MSCs in vitro, and determining whether the sample is able to induce at least some apoptosis to occur in live MSCs in vitro, or detection of elevated levels of prostaglandin E2 (PGE2). The ability of the sample to induce said apoptosis and / or elevated levels of PGE2 is indicative of responsiveness of said patient to said immunosuppressive treatment and / or indicative of fitness to recover. Also provided are apoptotic MSCs for use in the treatment of immune-mediated disease or conditions, such as allo-immune or autoimmune disease, or for the prevention or treatment of rejection of a transplanted organ; or in regenerative medicine to stimulate tissue repair. Methods for preparing pharmaceutical compositions comprising the apoptotic MSCs are also described and claimed.

The present disclosure describes a pharmaceutical composition comprising at least one antibody and at least one mesenchymal stromal cell-derived protein. Disclosed herein is also the use of said pharmaceutical composition for treating immunological diseases, for example alloimmune and autoimmune diseases. Further disclosed herein is the use of the pharmaceutical composition for immunomodulation.